Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053)
Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program
pharmaceutical investing Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results
SAGA Metals Completes Phase 2 of Major Drill Program at the Radar Project in Labrador-Confirms Extensive Oxide Mineralization in All Drill Locations at Trapper North and South Zones & Provides Corporate Update
ReeXploration Announces Field Program Results Confirming Large-Scale Uranium Target at Eureka, Namibia
